SGLT-2 Antibody (D-6): sc-393350

SGLT-2 Antibody (D-6) is a mouse monoclonal IgG1 kappa light chain antibody that detects SGLT-2 protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), and enzyme-linked immunosorbent assay (ELISA). SGLT-2 (D-6) antibody is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. SGLT-2, a member of the sodium-glucose cotransporter family, plays a crucial role in glucose reabsorption in the kidneys, specifically in the proximal convoluted tubule, where SGLT-2 facilitates the transport of glucose from the renal tubular fluid back into the bloodstream. This process is vital for maintaining glucose homeostasis, as SGLT-2 prevents excessive loss of glucose in urine, which can lead to conditions such as glucosuria. SGLT-2 operates by utilizing the sodium gradient established by the Na+/K+ ATPase pump, allowing for the co-transport of sodium ions and glucose molecules. Dysregulation or mutations in SGLT-2 can lead to familial renal glucosuria, a condition characterized by the presence of glucose in urine despite normal blood glucose levels, highlighting the importance of SGLT-2 in renal function and metabolic health.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SGLT-2 Antibody (D-6) References:

1. Expression characteristics and relevance of sodium glucose cotransporter-1 in mammalian renal tubulogenesis.  |  Yang, Q., et al. 2000. Am J Physiol Renal Physiol. 279: F765-77. PMID: 10997927
2. Status of glucose transporters in the mammalian kidney and renal development.  |  Wallner, EI., et al. 2001. Ren Fail. 23: 301-10. PMID: 11499546
3. Normal kinetics of intestinal glucose absorption in the absence of GLUT2: evidence for a transport pathway requiring glucose phosphorylation and transfer into the endoplasmic reticulum.  |  Stümpel, F., et al. 2001. Proc Natl Acad Sci U S A. 98: 11330-5. PMID: 11562503
4. The glucose transporter families SGLT and GLUT: molecular basis of normal and aberrant function.  |  Scheepers, A., et al. 2004. JPEN J Parenter Enteral Nutr. 28: 364-71. PMID: 15449578
5. A novel SGLT2 mutation in a patient with autosomal recessive renal glucosuria.  |  Francis, J., et al. 2004. Nephrol Dial Transplant. 19: 2893-5. PMID: 15496564
6. A novel missense mutation in SLC5A2 encoding SGLT2 underlies autosomal-recessive renal glucosuria and aminoaciduria.  |  Magen, D., et al. 2005. Kidney Int. 67: 34-41. PMID: 15610225
7. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.  |  Rahmoune, H., et al. 2005. Diabetes. 54: 3427-34. PMID: 16306358
8. Luminal glucose sensing in the rat intestine has characteristics of a sodium-glucose cotransporter.  |  Freeman, SL., et al. 2006. Am J Physiol Gastrointest Liver Physiol. 291: G439-45. PMID: 16675747
9. SGLT-2 inhibitors and the risk of infections: a systematic review and meta-analysis of randomized controlled trials.  |  Puckrin, R., et al. 2018. Acta Diabetol. 55: 503-514. PMID: 29484489
10. Role and mechanisms of SGLT-2 inhibitors in the treatment of diabetic kidney disease.  |  Dai, ZC., et al. 2023. Front Immunol. 14: 1213473. PMID: 37809091
11. UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE.  |  Roddick, AJ., et al. 2023. BMC Nephrol. 24: 310. PMID: 37880609
12. Assignment of the human Na+/glucose cotransporter gene SGLT1 to chromosome 22q13.1.  |  Turk, E., et al. 1993. Genomics. 17: 752-4. PMID: 8244393

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SGLT-2 Antibody (D-6) has 29 citations in a variety of scientific publications.

Primary antibodies like Anti-SGLT-2 Antibody (D-6) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SGLT-2 Antibody (D-6) Specifications

Alternate Product Name: SLC5A2

Product Clone Name: D-6

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 226-268

Epitope Target: SGLT-2

Epitope Species: human

Product Reactivity/Detection: SGLT-2

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 29 citations in various scientific publications

Available Conjugates/Forms for SGLT-2 Antibody (D-6): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin